Risperdal settlement to cost J&J $181 millionRisperdal to providers treating patients with Alzheimer's and dementia, Reuters reported. The drug, which is intended to treat schizophrenia, is not approved for these conditions.
The Centers for Medicare & Medicaid Services recently announced that Medicare will now support the simultaneous use of smartphone applications with continuous glucose monitors.
Arjo is launching its own dedicated long-term care division.
Bulk TV & Internet is merging with another player in the field.